reports
- Damien Choplain
- Martial Descoutures
- Damien Choplain
- Martial Descoutures
RHM RHEINMETALL AG
BLND BRITISH LAND COMPANY PLC
GRF GRIFOLS S.A. CLASS A
ELE ENDESA S.A.
ISP INTESA SANPAOLO S.P.A.
TLX TALANX AG
UCG UNICREDIT S.P.A.
CABK CAIXABANK SA
GRF.P GRIFOLS S.A. PREF CLASS B
ARGX ARGEN-X SE
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
SGSN SGS SA
- Damien Choplain
- Martial Descoutures
Argenx : Efgartigimod enters phase III in myositis
>Positive phase II results - Argenx has announced positive results for the phase II of the phase II/III study (ALKIVIA) evaluating efgartigimod in patients with three sub-types of idiopathic inflammatory myopathies (or myositis). With no quantified press release for the time being, the group has indicated that the study demonstrates a statistically significant therapeutic effect in favour of efgartigimod on the total improvement score (TIS) at week 24 (primary endpoin...
- Hilde Van Boxstael
- Michiel Declercq
- Sharad Kumar S.P
- Thomas Vranken
- Wim Lewi
- Damien Choplain
- Martial Descoutures
Argenx : Efgartigimod passe en phase 3 dans les myosites
>Résultats de phase 2 positifs - Argenx annonce des résultats positifs de la partie phase 2 de la phase 2/3 (ALKIVIA) évaluant efgartigimod chez des patients dans trois sous-types de myopathies inflammatoires idiopathiques (ou myosites). Sans communiqué de résultats chiffrés à ce stade, la société indique que l’étude a démontré un effet thérapeutique en faveur d’efgartigimod statistiquement significatif sur le score total d’amélioration (TIS) à la semaine 24 (critère ...
- Thomas Vranken
argenx Myositis go & model update
argenx announced that it is advancing clinical development of SC efgar in idiopathic inflammatory myopathies (myositis). The ongoing seamless Ph2/3 study is a basket trial across three myositis subsets, IMNM, ASyS and DM, each of which will continue into the Ph3 part. Furthermore, following the strong Q3 update, we have adjusted our model to reflect the sustained strong commercial uptake for Vyvgart in myasthenia gravis (MG), as well as the solid start in CIDP. On the other hand, we have removed...
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic ...
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIAPotential for efgartigimod SC to be first targeted approach for myositis patients who have limited treatment options November 20, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune dise...
- Pierre FerraguÊ
ASML 2024 CMD: What did we learn?
ASML hosted its 2024 CMD last week. This note follows our initial reaction on the company’s updated financial targets and our recent updated perspective on the broader semicap equipment sector and ASML. The event was particularly rich and will provide us with research topics for months to come. For a summary of our main takeaways, please follow the link below.
- Ahmed Ben Salem
- Bruno Cavalier
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
VOLV B VOLVO AB CLASS B
MRK MERCK KGAA
EOAN E.ON SE
ALO ALSTOM SA
ENI ENI S.P.A.
REP REPSOL SA
ANA ACCIONA SA
MERLIN MERLIN PROPERTIES SOCIMI S.A.
SIE SIEMENS AG
ASML ASML HOLDING NV
BP. BP P.L.C.
REY REPLY S.P.A.
LAND LAND SECURITIES GROUP PLC
BNTX BIONTECH SE
ANE CORPORACION ACCIONA ENERGIAS RENOVABLES SA
SHEL SHELL PLC
AGN AEGON N.V.
- Ahmed Ben Salem
ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 11/15/2024
Swiss-based Accelleron was formed from the spin-off of ABB’s highly profitable turbocharger division in 2022. We view the share as a promising investment on 1/ market leadership in an attractive niche, 2/ about ~40% ROCE, 3/ conversion of ~80% of EBITDA into cash, leading to fast deleveraging, and a solid base for shareholder remuneration (75% pay out), and 4/ strong long-term visibility linked to a ~75% service share, the bulk of which is recurring. Despite an already strong stock pe...
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
VOLV B VOLVO AB CLASS B
MRK MERCK KGAA
EOAN E.ON SE
ALO ALSTOM SA
ENI ENI S.P.A.
REP REPSOL SA
ANA ACCIONA SA
MERLIN MERLIN PROPERTIES SOCIMI S.A.
SIE SIEMENS AG
ASML ASML HOLDING NV
BP. BP P.L.C.
REY REPLY S.P.A.
LAND LAND SECURITIES GROUP PLC
BNTX BIONTECH SE
ANE CORPORACION ACCIONA ENERGIAS RENOVABLES SA
SHEL SHELL PLC
AGN AEGON N.V.
- Alvaro del Pozo
- Martin Marandon-Carlhian
- Stephane Houri
ASML : Successful CMD, outlook broadly unchanged, but much more AI-exp...
>Outperform rating maintained after CMD, TP € 950, or 41% upside - ASML yesterday held its 2024 CMD, during which it reaffirmed its 2030 guidance (issued initially in 2022) for revenues of € 44-60bn and a gross margin of 56-60%. This confirmation, coming less a month after the warning on 2025, was a relief (stock at +7%), as the group’s long-term outlook remains as solid. We found the new management very clear on what has changed since 2022, i.e. negatives with market...
- Research Department
INFORME DIARIO 15 NOVIEMBRE + RDOS. ESPAÑA 3T’24. PREVIEWS (ANÁLISIS B...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ACCIONA, ACCIONA ENERGÍA, CAF, CAIXABANK, COLONIAL, MERLIN. EUROPA: ASML, SANOFI. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 3T’24 que se publicarán en España y Europa en los próximos días. El BCE con el objetivo casi cumplido El Euro STOXX 50 tuvo su mejor día desde finales de septiembre mientras las ...
- Martin Marandon-Carlhian
- Stephane Houri
ASML : Un CMD réussi, des perspectives globalement inchangées, mais av...
>Opinion Surperformance réitérée après le CMD, OC 950 €, soit un upside de 41% - Hier ASML a tenu son CMD 2024, au cours duquel le groupe a réitéré ses objectifs 2030 (donnés initialement en 2022) d’un CA de 44 à 60 Md€ et d’une marge brute de 56/60%. Cette confirmation, venant moins d’un mois après l’avertissement sur 2025, a été un soulagement (titre à +7%) car les perspectives LT du groupe sont toujours aussi solides. Nous avons trouvé le nouveau management très cl...
- Chaima Ferrandon
- Sven Edelfelt
FGR EIFFAGE SA
ALV ALLIANZ SE
TEP TELEPERFORMANCE SE
MRK MERCK KGAA
EOAN E.ON SE
ALO ALSTOM SA
RWE RWE AG
SAN SANOFI
NEX NEXANS SA
DTE DEUTSCHE TELEKOM AG
TIT TELECOM ITALIA S.P.A.
HLAG HAPAG-LLOYD AG
SIE SIEMENS AG
ASML ASML HOLDING NV
ALG ALLEGRO.EU SA
ENR SIEMENS ENERGY AG
DSY DASSAULT SYSTEMES SA
CVC CVC CAPITAL PARTNERS PLC
- Chaima Ferrandon
- Sven Edelfelt
FGR EIFFAGE SA
ALV ALLIANZ SE
TEP TELEPERFORMANCE SE
MRK MERCK KGAA
EOAN E.ON SE
ALO ALSTOM SA
RWE RWE AG
SAN SANOFI
NEX NEXANS SA
DTE DEUTSCHE TELEKOM AG
TIT TELECOM ITALIA S.P.A.
HLAG HAPAG-LLOYD AG
SIE SIEMENS AG
ASML ASML HOLDING NV
ALG ALLEGRO.EU SA
ENR SIEMENS ENERGY AG
DSY DASSAULT SYSTEMES SA
CVC CVC CAPITAL PARTNERS PLC
- Martin Marandon-Carlhian
- Stephane Houri
ASML : 2030 guidance totally unchanged, not even a more precise one…
>ASML confirms its 2030 targets of € 44/60bn of revenues and a gross margin between 56% and 60% - ASML has just released a press release ahead of its CMD this afternoon (starting at 1 p.m. CET) and here are the key highlights: ASML confirms potential 2030 scenarios for annual revenue between approximately € 44bn and € 60bn, with a gross margin of between approximately 56% and 60%. The mid point of € 52bn is thus unchanged. Consensus for sales is still at around €...
- Martin Marandon-Carlhian
- Stephane Houri
ASML : 2030 guidance totally unchanged, not even a more precise one…
>ASML confirms its 2030 targets of € 44/60bn of revenues and a gross margin between 56% and 60% - ASML has just released a press release ahead of its CMD this afternoon (starting at 1 p.m. CET) and here are the key highlights: ASML confirms potential 2030 scenarios for annual revenue between approximately € 44bn and € 60bn, with a gross margin of between approximately 56% and 60%. The mid point of € 52bn is thus unchanged. Consensus for sales is still at around €...
- Jan Frederik Slijkerman
- Jeroen van den Broek
- Jesse Norcross
- Nadège Tillier
- Timothy Rahill
- ING Helpdesk
Benelux Morning Notes
Agfa-Geveart: Material miss on Healthcare activities. ASML: Long-term guidance confirmed. CVC Capital Partners: Comfortably on track. DEME Group: Raises outlook, lowers capex guidance. Proximus: Pressure on CEO from another possible coalition party. SBM Offshore: Again delivering
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.